Occult tumor cells detected in autologous blood stem cell harvests have no impact on 5 year outcomes for breast cancer patients with 4-9 positive nodes treated with adjuvant high-dose therapy and stem cell transplantation

Bone Marrow Transplantation

Volumn 31, Issue 7, 2003, Pages 571-574

  Reed, E ^a   Kessinger, A ^a   Murphy, B ^b   Tarantolo, S ^a   Traystman, M ^a   Sharp, J Graham ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autograft; Breast cancer; Tumor cell

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTOKERATIN; DOXORUBICIN; ETOPOSIDE;

ADULT; APHERESIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OCCULT CANCER; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; STEM CELL;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT REMOVAL; BREAST NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0037729007     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703878     Document Type: Review

References (21)

1. Nemoto T, Vana J, Bedwani R et al. Management and survival of female breast cancer; results of a national survey by the American College of Surgeons. Cancer 1980; 45: 2917-2924.
2. Schumacher M, Bastert G, Bojar H et al. Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol 1994; 12: 2086-2093.
3. Peters W, Rosner G, Vredenburgh J et al. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13. Proc ASCO 1999; 18: 1a (abstr 2).
4. Diel IJ, Kaufmann M, Costa SD et al. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996; 88: 1652-1658.
5. Braun S, Cevatli BS, Assemi C et al. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy. J Clin Oncol 2001; 19: 1468-1475.
6. Vredenburgh JJ, Silva O, Broadwater G et al. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 1997; 3: 91-97.
7. Sharp JG, Vaughan WP, Kessinger A et al. Significance of detection of tumor cells in hematopoietic stem cell harvests of patients with breast cancer. In: Dicke KA, Armitage JO, Dicke-Evenger MJ (eds). Autologous Bone Marrow Transplantation Proceedings of the Fifth International Symposium. The University of Nebraska Medical Center: Omaha, 1991, pp 385-391.
8. Solano C, Badia B, Lluch A et al. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant 2001; 27: 287-293.
9. Stadtmauer EA, Tsai DE, Sickles CJ et al. Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Med Oncol 1999; 16: 279-288.
10. Kasimir-Bauer S, Mayer S, Bojko P et al. Survival of tumor cells in stem cell preparations and bone marrow of patients with high-risk or metastatic breast cancer after receiving dose-intensive or high-dose chemotherapy. Clin Cancer Res 2001; 7: 1582-1589.
11. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
12. Passos-Coelho JL, Ross AA, Moss TJ et al. Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factor. Blood 1995; 85: 1138-1143.
13. Ross AA, Cooper BW, Lazarus HM et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patient using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605-2610.
14. Weaver CH, Moss T, Schwartzberg LS et al. High-dose chemotherapy in patients with breast cancer: evaluation of infusing peripheral blood stem cells containing occult tumor cells. Bone Marrow Transplant 1998; 21: 1117-1124.
15. Traystman MD, Cochran GT, Hake SJ et al. Comparison of molecular cytokeratin 19 reverse transcriptase polymerase chain reaction (CK19 RT-PCR) and immunocytochemical detection of micrometastatic breast cancer cells in hematopoietic harvests. J Hematother 1997; 6: 551-561.
16. Datta YH, Adams PT, Drobyski WR et al. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994; 12: 475-482.
17. Preti RA, Lazarus HM, Winter J et al. Tumor cell depletion of peripheral blood progenitor cells using positive and positive/negative selection in metastatic breast cancer. Cytotherapy 2001; 3: 85-95.
18. Burgess J, Mills B, Griffith M et al. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34+ cells. Cytotherapy 2001; 3: 285-294.
19. Chabannon C, Cornetta K, Lotz JP et al. High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood stem cells in patients with poor-prognosis breast cancer: a randomized multicentre study. Br J Haematol 1998; 78: 913-921.
20. Slade MJ, Smith BM, Sinnett HD et al. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer. J Clin Oncol 1999; 17: 870-879.
21. Kruger WH, Kroger N, Togel F et al. Disseminated breast cancer cells prior to and after high-dose therapy. J Hematother Stem Cell Res 2001; 10: 681-689.